Regeneron Pharmaceuticals (REGN) Projected to Post Earnings on Friday

Regeneron Pharmaceuticals (NASDAQ:REGN) is expected to be posting its Q2 2025 quarterly earnings results before the market opens on Friday, August 1st. Analysts expect Regeneron Pharmaceuticals to post earnings of $8.53 per share and revenue of $3.30 billion for the quarter.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. Regeneron Pharmaceuticals’s quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $9.55 EPS. On average, analysts expect Regeneron Pharmaceuticals to post $36 EPS for the current fiscal year and $38 EPS for the next fiscal year.

Regeneron Pharmaceuticals Trading Down 0.6%

NASDAQ:REGN opened at $554.58 on Thursday. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $59.87 billion, a PE ratio of 14.12, a price-to-earnings-growth ratio of 2.09 and a beta of 0.33. The firm’s 50 day moving average is $539.67 and its 200 day moving average is $606.17. Regeneron Pharmaceuticals has a 12 month low of $476.49 and a 12 month high of $1,211.20.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.63%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.96%.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Regeneron Pharmaceuticals stock. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 261.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 948 shares of the biopharmaceutical company’s stock after acquiring an additional 686 shares during the period. Brighton Jones LLC’s holdings in Regeneron Pharmaceuticals were worth $675,000 as of its most recent SEC filing. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the topic of a number of research reports. The Goldman Sachs Group lowered their price target on shares of Regeneron Pharmaceuticals from $917.00 to $804.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. UBS Group lifted their price target on shares of Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the stock a “neutral” rating in a report on Friday, July 11th. Guggenheim reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a report on Friday, May 30th. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $800.00 to $600.00 and set an “outperform” rating on the stock in a report on Monday, June 2nd. Finally, Royal Bank Of Canada cut shares of Regeneron Pharmaceuticals from a “moderate buy” rating to a “hold” rating and set a $662.00 price target on the stock. in a report on Friday, May 30th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $837.61.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.